Candel Therapeutics, Inc.
CADL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $125 | $125 |
| % Growth | – | -100% | 0% | – |
| Cost of Goods Sold | $990 | $23,980 | $0 | $14,594 |
| Gross Profit | -$990 | -$23,980 | $125 | -$14,469 |
| % Margin | – | – | 100% | -11,575.2% |
| R&D Expenses | $19,314 | $24,506 | $20,787 | $15,178 |
| G&A Expenses | $14,057 | $13,724 | $14,060 | $10,423 |
| SG&A Expenses | $14,057 | $14,411 | $14,060 | $11,257 |
| Sales & Mktg Exp. | $0 | $687 | $0 | $834 |
| Other Operating Expenses | -$990 | -$24,506 | $0 | -$15,178 |
| Operating Expenses | $32,381 | $14,411 | $34,847 | $11,257 |
| Operating Income | -$33,371 | -$38,391 | -$34,722 | -$25,726 |
| % Margin | – | – | -27,777.6% | -20,580.8% |
| Other Income/Exp. Net | -$21,806 | $452 | $15,928 | -$10,398 |
| Pre-Tax Income | -$55,177 | -$37,939 | -$18,794 | -$36,124 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$55,177 | -$37,939 | -$18,794 | -$36,124 |
| % Margin | – | – | -15,035.2% | -28,899.2% |
| EPS | -1.74 | -1.31 | -0.099 | -1.26 |
| % Growth | -32.8% | -1,217.9% | 92.1% | – |
| EPS Diluted | -1.74 | -1.31 | -0.099 | -1.26 |
| Weighted Avg Shares Out | 31,675 | 28,935 | 28,823 | 28,690 |
| Weighted Avg Shares Out Dil | 31,675 | 28,935 | 28,823 | 28,690 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,086 | $0 | $1,218 | $0 |
| Interest Expense | $2,090 | $514 | $1,708 | $53 |
| Depreciation & Amortization | $990 | $960 | $778 | $232 |
| EBITDA | -$52,097 | -$37,431 | -$16,308 | -$25,494 |
| % Margin | – | – | -13,046.4% | -20,395.2% |